Tables of Rules

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
Nucleoside and Nucleotide reverse transcriptase inhibitors Protease inhibitors

Non-Nucleoside reverse transcriptase inhibitors Fusion inhibitors

HIV - 2 Integrase inhibitors


  Mutations associated to resistance Mutations associated to « possible resistance »
EFV
 L100I
K101E
K103H/N/S/T [1]
V106M [2]
Y181C/I
Y188C/L
G190A/C/E/Q/S/T/V
P225H
M230L
NVP
 A98S (for HIV-1 subtype C only) [3]
L100I
K101E
K103H/N/S/T [1]
V106A/M [2]
Y181C/I
Y188C/H/L
G190A/C/E/Q/S/T/V
M230L		 A98S (for other subtypes than HIV-1 subtype C) [3]

ETV
TMC125
At least 4 among: V90I, A98G, L100I, K101E/P,  V106I, V179D/F, Y181C/I/V, G190A/S [4]
3 mutations among: V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V, G190A/S [4]

EFV: efavirenz, NVP: nevirapine, ETV (TMC125): etravirine
Mutations associated to antiretroviral regimen but with uncertain signification: K101H/N/P/Q

References